A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
AGIOS PHARMACEUTICALS, INC.
AGIO
$2.1B
Mkt Cap
$36.36
+0.22%
AGIOS PHARMACEUTICALS, INC. (AGIO) has a 5-year average return on invested capital (ROIC) of 32.1%. This indicates strong capital allocation and a potential competitive advantage.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a market capitalization of $2.2B. It is classified as a mid-cap stock.
AGIOS PHARMACEUTICALS, INC. (AGIO) does not currently pay a regular dividend.
AGIOS PHARMACEUTICALS, INC. (AGIO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AGIOS PHARMACEUTICALS, INC. (AGIO) generated $-377 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
AGIOS PHARMACEUTICALS, INC. (AGIO) reported earnings per share (EPS) of $-7.12 in its most recent fiscal year.
AGIOS PHARMACEUTICALS, INC. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 66M | - | - | - | - | 0 |
| Net Income | -423M | -413M | 674M | -352M | -232M | 1.6B |
| EPS | $-7.22 | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
| Free Cash Flow | -385M | -377M | 388M | -297M | -314M | -413M |
| ROIC | -31.7% | -30.2% | 57.3% | -36.8% | -19.4% | 189.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.03 | 0.04 | 0.16 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -476M | -472M | -426M | -391M | -389M | -378M |
| Operating Margin | -720.0% | - | - | - | - | - |
| ROE | -38.1% | -30.2% | 57.3% | -36.8% | -19.4% | 189.7% |
| Shares Outstanding | 59M | 58M | 58M | 56M | 55M | 60M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 65M | 59M | N/A | N/A | N/A | N/A | 0 | 0 | N/A | N/A | N/A | N/A | 66M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 100M | 142M | 220M | 293M | 341M | 214M | 221M | 257M | 280M | 296M | 301M | 340M | 348M |
| SG&A | 19M | 36M | 51M | 71M | 114M | 102M | 115M | 121M | 122M | 120M | 157M | 180M | 187M |
| EBIT | -54M | -119M | -201M | -321M | -362M | -316M | -336M | -378M | -389M | -391M | -426M | -472M | -476M |
| Op. Margin | -82.8% | -200.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -720.0% |
| Net Income | -54M | -118M | -198M | -315M | -346M | -411M | -327M | 1.6B | -232M | -352M | 674M | -413M | -423M |
| Net Margin | -81.9% | -199.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -639.8% |
| Non-Recurring | 0 | -33K | 0 | -40K | -20K | -1.1M | 0 | 6.6M | 0 | 0 | 200M | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -19.3% | -30.6% | -56.4% | -85.7% | -65.1% | -61.9% | -62.9% | 189.7% | -19.4% | -36.8% | 57.3% | -30.2% | -31.7% |
| ROE | -19.3% | -30.6% | -56.4% | -85.7% | -65.1% | -62.0% | -63.0% | 189.7% | -19.4% | -36.8% | 57.3% | -30.2% | -38.1% |
| ROA | -15.4% | -25.8% | -38.2% | -51.0% | -47.0% | -47.0% | -37.5% | 140.1% | -17.3% | -32.4% | 51.8% | -27.9% | -35.7% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -59M | -77M | 39M | -285M | -304M | -371M | -291M | -407M | -309M | -296M | 390M | -373M | -380M |
| Free Cash Flow | -62M | -97M | 29M | -290M | -311M | -383M | -305M | -413M | -314M | -297M | 388M | -377M | -385M |
| Owner Earnings | -72M | -117M | -17M | -339M | -385M | -437M | -362M | -470M | -367M | -347M | 341M | -431M | -497M |
| CapEx | 2.2M | 20M | 9.9M | 4.6M | 7.0M | 12M | 14M | 5.7M | 4.9M | 999K | 1.7M | 4.3M | 4.3M |
| Maint. CapEx | 1.4M | 7.7M | 13M | 6.4M | 7.2M | 8.1M | 9.4M | 8.8M | 8.4M | 6.6M | 5.7M | 5.2M | 60M |
| Growth CapEx | 849K | 13M | 0 | 0 | 0 | 3.9M | 4.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 1.4M | 7.7M | 13M | 6.4M | 7.2M | 8.1M | 9.4M | 8.8M | 8.4M | 6.6M | 5.7M | 5.2M | 60M |
| CapEx/OCF | N/A | N/A | 25.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 802M | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 38.8% | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 12M | 32M | 42M | 48M | 73M | 58M | 62M | 54M | 49M | 45M | 43M | 53M | 57M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -685M | -693M | -1.5B | -1.2B | N/A | -1.5B | -1.2B | -1.1B |
| Cash & Equiv. | 14M | 72M | 161M | 103M | 71M | 81M | 127M | 203M | 139M | 88M | 76M | 89M | 1.1B |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | 673K | 331K | 276K | 0 | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.16 | 0.22 | 0.73 | 0.64 | 0.25 | 0.18 | 0.26 | 0.00 | 0.00 | 0.16 | 0.04 | 0.03 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 424M | 345M | 359M | 376M | 688M | 641M | 400M | 1.3B | 1.1B | 811M | 1.5B | 1.2B | 1.1B |
| Total Assets | 492M | 420M | 619M | 614M | 858M | 891M | 853M | 1.4B | 1.2B | 937M | 1.7B | 1.3B | 1.2B |
| Total Liabilities | 68M | 75M | 261M | 239M | 171M | 250M | 453M | 146M | 138M | 126M | 122M | 104M | 76M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -167M | -285M | -483M | -798M | -1.1B | -1.5B | -1.8B | -239M | -471M | -823M | -149M | -562M | -661M |
| Working Capital | 298M | 284M | 471M | 350M | 520M | 519M | 542M | 1.0B | 770M | 766M | 884M | 860M | 776M |
| Current Assets | 360M | 337M | 560M | 445M | 614M | 612M | 637M | 1.1B | 833M | 834M | 966M | 942M | 835M |
| Current Liabilities | 61M | 53M | 88M | 95M | 94M | 93M | 94M | 60M | 63M | 68M | 81M | 82M | 59M |
| Per Share Data | |||||||||||||
| EPS | -1.59 | -3.15 | -5.07 | -6.75 | -6.03 | -6.86 | -4.74 | 26.55 | -4.23 | -6.33 | 11.64 | -7.12 | -7.22 |
| Owner EPS | -2.15 | -3.12 | -0.43 | -7.28 | -6.71 | -7.28 | -5.24 | -7.77 | -6.70 | -6.25 | 5.90 | -7.43 | -8.38 |
| Book Value | 12.61 | 9.23 | 9.16 | 8.05 | 11.98 | 10.68 | 5.78 | 21.38 | 20.09 | 14.58 | 26.62 | 20.58 | 18.69 |
| Cash Flow/Share | -1.76 | -2.06 | 0.99 | -6.12 | -5.30 | -6.18 | -4.21 | -6.74 | -5.65 | -5.32 | 6.74 | -6.43 | -6.11 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 33.7M | 37.4M | 39.1M | 46.6M | 57.4M | 60.0M | 69.1M | 60.4M | 54.8M | 55.6M | 57.9M | 58.0M | 59.3M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.3 | N/A | N/A | 2.9 | N/A | -5.0 |
| P/FCF | N/A | N/A | 58.0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 5.0 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 9.1 | 6.8 | 4.6 | 7.5 | 3.8 | 4.5 | 7.7 | 1.6 | 1.3 | 1.6 | 1.3 | 1.4 | 1.9 |
| Price/Sales | 26.2 | 60.8 | N/A | N/A | N/A | N/A | 14.9 | N/A | N/A | N/A | N/A | N/A | 32.7 |
| FCF Yield | -1.6% | -4.1% | 1.7% | -10.3% | -12.0% | -13.2% | -9.9% | -20.0% | -21.8% | -23.4% | 20.1% | -23.2% | -17.8% |
| Market Cap | 3.9B | 2.4B | 1.7B | 2.8B | 2.6B | 2.9B | 3.1B | 2.1B | 1.4B | 1.3B | 1.9B | 1.6B | 2.2B |
| Avg. Price | 50.96 | 96.10 | 47.33 | 55.38 | 76.68 | 47.56 | 43.97 | 48.57 | 27.14 | 25.11 | 38.95 | 34.16 | 36.36 |
| Year-End Price | 114.43 | 63.13 | 42.42 | 60.62 | 45.30 | 48.48 | 44.54 | 34.20 | 26.26 | 22.79 | 33.40 | 28.02 | 36.36 |
AGIOS PHARMACEUTICALS, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 32.1%. At current prices, the estimated annualized return to fair value is +3.5%.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a return on equity (ROE) of -30.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for AGIOS PHARMACEUTICALS, INC. (AGIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a book value per share of $20.58, based on its most recent annual SEC filing.